ArticleArchives of toxicology2026
CpG-ODN/Coa-ASC16 nanostructured adjuvant platform as a safe and effective alternative in Bothrops diporus antivenom production.
Article in Archives of toxicology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
In the field of vaccines, adjuvants have been optimized to enhance immune responses while reducing adverse effects. Transferring these advances to antivenom production could improve antibody quality and animal welfare. Here, we evaluated a novel adjuvant platform, CpG-ODN/Coa-ASC16, which combines immunostimulatory CpG-ODN oligodeoxynucleotides with the biodegradable nanostructure Coa-ASC16, co-formulated with a hemorrhagic antigenic model based on Bothrops diporus venom (B.dV). Immunization with B.dV/CpG-ODN/Coa-ASC16 elicited IgG titers equivalent to those induced by Freund's adjuvant, with significantly higher IgG1 levels. Antibodies generated with both formulations exhibited progressively higher avidity, reflecting effective affinity maturation. Sera from B.dV/CpG-ODN/Coa-ASC16-immunized mice recognized major venom proteins and neutralized key toxic activities-proteolytic, coagulant, and indirect hemolytic-at levels comparable to Freund's-induced sera. Functionally, sera from B.dV/CpG-ODN/Coa-ASC16-immunized mice conferred protection against a lethal venom challenge, resulting in survival of a fraction of animals and prolonged time to death in non-survivors. Importantly, histopathological analyses revealed minimal tissue alterations in the mice treated with CpG-ODN/Coa-ASC16, in sharp contrast to the severe abscesses and granulomas caused by Freund's adjuvant. Overall, this study provides new evidence that CpG-ODN/Coa-ASC16 can be effectively combined with hemorrhagic Bothrops venom to generate robust, high-affinity antibodies that efficiently neutralize the major venom toxins while markedly reducing local tissue damage. These findings position CpG-ODN/Coa-ASC16 as a safer and ethical alternative platform for antivenom production.
Indexed as
Identifiers
42159745What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.